9 U.S. lawmakers have disclosed 14 Vertex Pharmaceuticals Incorporated trades under the STOCK Act — 7 buys and 7 sells between 2013 and 2026. Congress has been evenly split of VRTX, and their disclosed buys are up 26.4% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of VRTX, marked to the latest close — per-share (share counts aren't disclosed).
Lawmakers ranked by notional-weighted return on their disclosed VRTX buys (last ~3y), marked to the latest close.
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-03-27 | Alan Armstrong | BUY | $1K–$15K | $433.07 | $516.44 2026-08-13 | +19.3% |
| 2025-08-07 | David J. Taylor | BUY | $1K–$15K | $375.63 | $516.44 2026-08-13 | +37.5% |
| 2025-01-17 | Rohit Khanna | BUY | $1K–$15K | $422.00 | $516.44 2026-08-13 | +22.4% |
| 2024-05-03 | Thomas H Tuberville | SELL | $1K–$15K | $401.08 | $516.44 2026-08-13 | -28.8% exit |
| 2024-05-03 | Thomas H Tuberville | SELL | $1K–$15K | $401.08 | $516.44 2026-08-13 | +34.3% rt |
| 2022-12-07 | Byron Donalds | BUY | $1K–$15K | $317.58 | $516.44 2026-08-13 | +62.6% |
| 2022-10-06 | Thomas H Tuberville | BUY | $1K–$15K | $298.63 | $516.44 2026-08-13 | +72.9% |
| 2022-03-29 | William R. Keating | BUY | $1K–$15K | $257.98 | $516.44 2026-08-13 | +100.2% |
| 2019-09-19 | Josh Gottheimer | SELL | $1K–$15K | $176.14 | $516.44 2026-08-13 | -193.2% exit |
| 2019-02-04 | John F Reed | SELL | $1K–$15K | $187.98 | $516.44 2026-08-13 | -174.7% exit |
| 2019-01-31 | Gilbert Cisneros | SELL | $1K–$15K | $190.91 | $516.44 2026-08-13 | -170.5% exit |
| 2018-03-09 | John F Reed | SELL | $1K–$15K | $176.26 | $516.44 2026-08-13 | -193.0% exit |
| 2015-05-13 | John F Reed | SELL | $1K–$15K | $125.52 | $516.44 2026-08-13 | -311.4% exit |
| 2013-03-25 | JOHN F REED | BUY | $1K–$15K | $54.26 | $516.44 2026-08-13 | +851.8% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
9 members of the U.S. House and Senate have disclosed Vertex Pharmaceuticals Incorporated transactions under the STOCK Act — 7 purchases and 7 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a VRTX purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed VRTX buys are up 26.4% versus the latest close of $516.44. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded VRTX and how it performed.